EUCTR2017-001171-23-GB进行中（未招募）1 期
A multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate. - FLIGHT Study, V1.0
niversity Hospitals Bristol NHS Foundation Trust0 个研究点目标入组 120 人开始时间: 2017年7月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients (males and females) >16 years old with a diagnosis of ITP, a platelet count <30x10^9/L AND a clinical need for first line treatment.
- •Patients have provided written informed consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •The exclusion criteria include pregnancy and breastfeeding
- •Patients with HIV, Hepatitis B or C, or Common Variable immunodeficiency.
- •Women of child bearing potential require a pregnancy test result within 7 days prior to randomisation to rule out unintended pregnancy
- •Contraindications to MMF or steroid including patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients or active significant infection
- •Patients not capable of giving informed consent (e.g. due to incapacity)
- •Patients unwilling to follow contraceptive advice if allocated to MMF treatment arm:
- •WOMEN: Because of the genotoxic and teratogenic potential of MMF, women of childbearing potential must be willing to use a highly effective method of contraception before and six weeks after stopping MMF (hormonal or barrier method of birth control; abstinence). Contraceptive methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods.
- •NB: Women are considered not of child bearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.
- •MEN: Sexually active men with female partners that are potentially child bearing are recommended to use condoms during treatment and for at least 90 days after cessation of treatment. Condom use applies for both reproductively competent and vasectomised men, because the risks associated with the transfer of seminal fluid also apply to men who have had a vasectomy. In addition, female partners of male patients treated with MMF are recommended to use highly effective contraception during treatment and for a total of 90 days after the last dose of MMF.
研究者
相似试验
招募中
3 期
Primary endoscopic hemostasis after EST between balloon tamponade technique and self-assembling peptidePerformance status 0 to 3Bleeding, Endoscopic sphincterotomy, Endoscopic retrograde cholangiopancreatography, PuraStatD006470JPRN-jRCTs052230103Ogura Takeshi130
进行中（未招募）
不适用
A multi-centre randomised trial of therapeutic intervention at primary HIV-1 infection - SPARTACHIV infectionMedDRA version: 8Level: LLTClassification code 10020161EUCTR2004-000446-20-IEImperial College360
已完成
不适用
Ondansetron for the treatment of irritable bowel syndrome (IBS) with diarrhoea (IBS-D): identifying the responderIrritable bowel syndromeISRCTN22664524niversity of Nottingham (UK)150
已完成
不适用
Internet-based relapse prevention for in-patients with anorexia nervosaSevere anorexia nervosa (AN)Mental and Behavioural DisordersEating disordersISRCTN18274621South London and Maudsley NHS Foundation Trust (UK)98
进行中（未招募）
1 期
Prospective randomised trial of first line treatments of Helicobacter pylori infection in SloveniaEUCTR2019-001914-41-SISlovensko Združenje za gastroenterologijo in hepatologijo280